Correlation of cell cycle-related kinase and SII with FIGO stage, lymph node metastasis, and prognosis of serous ovarian cancer.

Background: Ovarian cancer has no specific manifestations in the early stage, and most patients have advanced to the advanced stage when diagnosed for the first time. The 5-year survival rate for patients receiving standardized treatment is still low. The systemic immune inflammation index (SII) can comprehensively reflect host inflammation and immune balance status, and has good application value in evaluating the condition and prognosis of various malignant tumors. Cell cycle related kinase (CCRK) can regulate cell cycle, promote cell proliferation and division, and is closely related to the occurrence and development of various malignant tumors. Therefore, to detect the positive expression of CCRK and the level of SII index in serous ovarian cancer tissue, and to explore the relationship between CCRK and SII with the pathological characteristics and prognosis of serous ovarian cancer, analyze the possible mechanisms of CCRK and SII in the occurrence and development of serous ovarian cancer, and provide reference for clinical diagnosis and treatment of ovarian cancer.

Methods: The malignant group included 315 patients with serous ovarian cancer who were hospitalized by us from January 2018 to January 2019, and 158 patients with ovarian serous cystadenoma were enrolled in the benign group. During the operation, the cancerous foci and lesion tissues of the two groups were collected. The expression of CCRK in pathological tissues was detected by immunohistochemistry. CCRK expression and SII levels in the benign and malignant groups, and patients with different clinicopathologic features of serous ovarian cancer were compared. Taking the average SII level of the malignant group as the grouping standard, the invalids were divided into SII high- and low-expression groups and observed until January 2022. To analyze the correlation between CCRK expression, SII, FIGO stage, lymph node metastasis, and prognosis of serous ovarian cancer. The survival of patients with CCRK-positive and -negative expression of this disease, and SII high and low expressions were statistically analyzed.

Results: Positive CCRK expression was more prevalent in serous ovarian cancer tissues than in serous cystadenoma tissues, and the CCRK-positive grade in serous ovarian cancer was higher than that of cystadenoma. SII of patients with this disease was greater than that of those with serous cystadenoma and the difference was statistically significant (P < 0.05). FIGO stage and lymph node metastases were associated with positive expression of CCRK in serous ovarian cancer (P < 0.05). SII was correlated with FIGO stage, differentiation degree, lymph node metastasis, and serum CA125 level (P < 0.05). Spearman correlation analysis showed that the expression of CCRK in invalids with serous ovarian cancer was positively correlated with FIGO stage and lymph node metastasis of serous ovarian cancer (r = 0.538, r = 0.605, P < 0.001). SII was positively correlated with FIGO stage and lymph node metastasis of serous ovarian cancer (r = 0.689, r = 0.622, P < 0.001). The Kaplan-Meier survival curve and the log-rank test demonstrated that the CCRK-positive expression group had an lower survival rate than the CCRK-negative expression group, and that the SII high-expression group had an lower survival rate than the SII low-expression group (rank = 19.504, 16.184, P < 0.05).

Conclusion: Positive CCRK expression and an elevated SII have a role in the development of serous ovarian cancer and have the potential to predict the prognosis of patients.